Clinical Trial Search

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging — 0.0185; 0.0103…

Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001

Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3.1; 3.2 events/participant

Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade

Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90

Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min

Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min

Primary: Change in Peak VO2 (Oxygen Consumption ) — 1.21; 0.48 ml/kg/min

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Arbitrary Accelerometry Units (AAU) (Phase I) — 9370; 9538 accelerometry units

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Rate of Heart Failure Related (HFR) Hospitalizations — 0.32; 0.44 HFR hospitalizations/patient/6 months — p=0.0002

Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid

Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002

Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236

Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…

Primary: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date — 249; 356…

Primary: Freedom From Device/System Related Complications — 304 Participants

Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water

Primary: Change of the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores in Patients Newly Treated With Empagliflozin According to Routine Practice — 14.66; 17.61; 16.47…

Primary: Functional Test — 115.91; 57.25 feet

Primary: Exercise Treadmill Time — 621; 580; 624; 579 seconds — p=0.90

Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants

Primary: Rate of Cardiovascular Mortality and Heart Failure Morbidity — .46; .48 Rate of Events Per Patient-Year — p=0.82

Primary: Myocardial Energetic Efficiency — 48621.3; 50035.7; 50301.0; 52942.8 (((mmhg x ml x bpm) /g)/(1/min))

Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and…

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001